Clearside Biomedical Schedules Conference Call to Review Topline Results from Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis
Clearside is pleased to invite all interested parties to participate in a conference call at
Uveitis, a set of inflammatory conditions affecting the eye, is one the world’s leading causes of blindness. Uveitis occurs in about 350,000 patients in
PEACHTREE, a randomized, masked, sham-controlled Phase 3 trial, enrolled 160 patients with macular edema associated with non-infectious uveitis. Patients were randomized to receive two unilateral suprachoroidal CLS-TA injections or two unilateral suprachoroidal sham procedures approximately 12 weeks apart. The primary efficacy outcome measure in the trial is the proportion of patients with a change from baseline of at least 15 letters in BCVA using the ETDRS scale at 24 weeks. Safety will be assessed by analyzing the occurrence of adverse events and changes in key safety parameters over the course of the trial. Additional efficacy and safety endpoints will also be evaluated.
Chief Financial Officer
Source: Clearside Biomedical, Inc.